Cargando…
Sudapyridine (WX-081), a Novel Compound against Mycobacterium tuberculosis
Bedaquiline (BDQ) was historically listed by the World Health Organization (WHO) in 2018 as the preferred option for rifampin-resistant tuberculosis (RR-TB) and multidrug-resistant tuberculosis (MDR-TB). However, when there is no other effective regimen, the side effects and weaknesses of BDQ limit...
Autores principales: | Yao, Rong, Wang, Bin, Fu, Lei, Li, Lei, You, Kejun, Li, Yong-Guo, Lu, Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849072/ https://www.ncbi.nlm.nih.gov/pubmed/35170994 http://dx.doi.org/10.1128/spectrum.02477-21 |
Ejemplares similares
-
Antibacterial activity of the novel compound Sudapyridine (WX-081) against Mycobacterium abscessus
por: Nie, Wenjuan, et al.
Publicado: (2023) -
In vitro and Intracellular Antibacterial Activity of Sudapyridine (WX-081) Against Tuberculosis
por: Xiao, Hua, et al.
Publicado: (2023) -
In Vitro Activity of the Sudapyridine (WX-081) against Non-Tuberculous Mycobacteria Isolated in Beijing, China
por: Zhu, Rui, et al.
Publicado: (2022) -
wxPython in action
por: Rappin, Noel, 1971-
Publicado: (2006) -
wxPython in Action
por: Rappin, Noel, et al.
Publicado: (2006)